San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
Vivace Therapeutics, a San Mateo, CA-based biotech that has kept quiet about its research until now, has reached across the Pacific Ocean to close $25 million in financing to support its work…
[[Click headline to continue reading.]]
SAN FRANCISCO, June 28, 2017 /PRNewswire/ — Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its participation in the following upcoming investor conferences:
- Piper Jaffray GenomeRx Symposium
Panel: Gene Therapy – Tackling Manufacturing
July 11, 2017, 11:20 am ET
The Lotte New York Palace, New York
- Wedbush PacGrow Healthcare Conference
August 15, 2017, 12:45 pm ET
Le Parker Meridien Hotel, New York
To access a live webcast of the corporate presentation at the Wedbush PacGrow Healthcare Conference, please visit the Events & Presentations page within the Investors & News section of the Audentes website. A replay of the live webcast will be available on the Audentes website for approximately 30 days following the conference. There is no webcast available for the Gene Therapy – Tackling Manufacturing panel at the Piper Jaffray GenomeRx Symposium.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.
For more information regarding Audentes, please visit www.audentestx.com.
Thomas Soloway, CFO
SOURCE Audentes Therapeutics, Inc.
Genome sequencing is becoming more common for people diagnosed with cancer. Should it become part of a healthy person’s checkup, too? A new study published Monday in the Annals of Internal…
[[Click headline to continue reading.]]
Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics
Financing raised in two venture rounds, featuring leading investors from the U.S. and China
SAN MATEO, Calif., June 28, 2017 /PRNewswire/ — Vivace Therapeutics, an oncology-focused portfolio-based drug discovery and development company is coming out of stealth with $40 million raised in Series A and B financings. The company brings together leading scientists, investors and executives from the U.S. and China for a capital-efficient approach to developing novel cancer treatments.
The $25 million Series B was led by new investor Cenova Capital and included Sequoia Capital China and existing investors Canaan Partners, WuXi Healthcare Ventures and Mission Bay Capital. Canaan Partners and WuXi Healthcare Ventures co-led the company’s $15 million Series A in 2015.
“Since our founding, we have focused on bringing together the best experts from China and the U.S. to turn novel biology into first-in-class cancer therapeutics,” said Sofie Qiao, Ph.D., president and CEO of Vivace. “I am thrilled to team up with my academic co-founders, as well as Dr. Leonard Post on yet another oncology company, following my previous collaboration with Dr. Post on LEAD Therapeutics, which led to the discovery of Talazoparib.”
Vivace is initially concentrating on inhibitors of the Hippo-YAP signaling pathway, which plays a crucial role in cell development, and genetic mutations of the pathway give rise to a variety of cancers. Hippo-Yap pathway expert and Vivace scientific co-founder, Dr. Kun-liang Guan of the University of California, San Diego, recently discovered additional potential immuno-oncology applications by activating the pathway. Vivace is exploring both inhibition and activation of the pathway.
The company is also developing novel therapeutic antibodies — called BINspecific™ antibodies (bi-specific irreversible cell-type specific antibodies)— that bind in a nearly irreversible and cell-type specific manner to target cells. Discovered in the laboratory of Vivace’s scientific co-founder, Bin Liu, Ph.D., of the University of California, San Francisco, these antibodies can achieve super potent inhibition and cellular selectivity of specific targets, creating a superior therapeutic index.
“We are pleased with the progress Vivace has made since we and Canaan Partners co-founded the company in 2015,” said Edward Hu, Founding Partner of WuXi Healthcare Ventures and a founding member of Vivace’s board of directors. “It is great to have leading Chinese investors Cenova Capital and Sequoia Capital China join us.”
“These are novel, high impact programs where we can show activity in Phase 1 in molecularly selected patients, giving us an early development read on these transformative therapies,” said Tim Shannon, M.D., General Partner at Canaan and a founding member of Vivace’s board of directors. “With business and scientific leadership in the U.S., and research capabilities in China, Vivace takes an efficient and innovative approach to drug discovery.”
About Vivace Therapeutics
Vivace Therapeutics is an oncology-focused portfolio-based drug discovery and development company. Headquartered in San Francisco Bay Area, Vivace embraces a capital efficient virtual business model and conducts research in both small molecules and biologics, based on innovative science from the laboratories of the academic founders Dr. Kun-liang Guan of University of California, San Diego, Dr. Sheng Ding and Dr. Bin Liu of University of California, San Francisco. The company’s experienced management team and world-class scientists work efficiently to advance promising drugs, with the goal of conquering cancer. For more information, visit www.vivacetherapeutics.com.
SOURCE Vivace Therapeutics
SAN DIEGO, June 27, 2017 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, today announced the appointment of Neil Reisman to the Company’s Board of Directors, effective immediately.
Mr. Reisman is a lawyer and Certified Public Accountant with over 30 years of business experience with emphasis on finance, operations, legal, tax and transactional experience. He will provide similar guidance while serving on Mirati’s Board of Directors.
“Neil is an accomplished business leader and advisor,” said Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics. “We are pleased to add his talents and extensive experience to our Board of Directors and confident Mirati will benefit from his insights and counsel.”
Mr. Reisman is a managing director and member of the Tavistock Group Board of Directors. He joined Tavistock in 2004 as Chief Operating Officer/Chief Financial Officer/General Counsel at CovX, a biotechnology company located in San Diego. Over the years, he has assumed various operational roles at companies within Tavistock Group and various other roles at the Tavistock Group, including chairing its Investment Committee as well as having the offices of the General Counsel and Chief Financial Officer report to him. He is currently Chairman of the Board of Nucleus Biologics. Mr. Reisman received his JD in 1986 from the University of Pennsylvania Law School and his BS in Accountancy in 1983 from the University of Illinois.
About Mirati Therapeutics
Mirati Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer. This approach is transforming the treatment of patients by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and migration. Our precision oncology programs seek to treat the patients most likely to benefit from targeted oncology treatments and are driven by drugs that target very specific genetic mutations, directed by genomic tests that identify patients who carry those driver mutations. Our immuno-oncology programs are novel small molecule drugs designed to enhance and expand the efficacy of checkpoint inhibitors when given in combination. In addition to our clinical programs, we have active discovery research efforts focused on novel oncology targets. The promise of these approaches includes potentially better patient outcomes, more efficient cancer treatment and faster drug development. For more information, visit www.mirati.com.
SOURCE Mirati Therapeutics, Inc.
SAN FRANCISCO, June 27, 2017 /PRNewswire/ — Committed to expanding access to the highest quality of fertility care available, the CCRM Network is opening a new location in the San Francisco Bay Area on June 28. CCRM San Francisco is co-founded by board certified reproductive endocrinologists Salli Tazuke, M.D. and Sunny Jun, M.D. The new facility houses an all-inclusive fertility treatment center with a dedicated on-site physician team, IVF laboratory, procedures area, and comprehensive diagnostic services.
Founded in 1987 by William Schoolcraft, M.D., CCRM achieves some of the highest pregnancy success rates in the nation. In addition to the San Francisco office, CCRM currently has locations in Atlanta, Boston, Colorado, Houston, Minneapolis, New York, Orange County, and Toronto, Canada. A new office in Northern Virginia is expected to open July 2017.
“We are proud that we continue to attract talented physicians who share our dedication to clinical excellence within our communities,” said Dr. Schoolcraft. “Drs. Tazuke and Jun are two of the most talented physicians in the Bay Area and they are a great addition to the CCRM team.”
Dr. Tazuke received her undergraduate degree from Stanford University and her medical degree from University of California San Diego. She completed her residency at Yale University School of Medicine and her fellowship in reproductive endocrinology and infertility at Stanford University School of Medicine. Dr. Tazuke is fluent in Japanese and conversant in Mandarin and Spanish.
“CCRM has some of the highest success rates in the industry and is continuously developing groundbreaking techniques to improve fertility medicine,” said Dr. Tazuke. “We are delighted to team up and partner with such a renowned group of physicians, embryologists and researchers.”
Dr. Jun received her combined B.A/M.D degrees from Boston University. After completing her residency in obstetrics and gynecology at Stanford University School of Medicine, she then stayed at Stanford to complete her fellowship in reproductive endocrinology and infertility. Dr. Jun is fluent in Korean and conversant in Spanish.
“We are incredibly excited to be a part of the CCRM Network. Families from across the Bay Area will now have the opportunity to have convenient access to a world-class fertility treatment center and ultimately, the best possible chance of having a healthy baby,” said Dr. Jun.
CCRM San Francisco is located at 1060 Marsh Road, 1st Floor in Menlo Park. To schedule an appointment, call 650-646-7500 or visit ccrmivf.com.
About CCRM San Francisco
CCRM San Francisco is a partner clinic of the Colorado Center for Reproductive Medicine (“CCRM”). Founded in 1987 by Dr. William Schoolcraft, CCRM is recognized as one of the top fertility treatment centers in the nation, providing a wide spectrum of infertility treatments ranging from basic infertility care to advanced in vitro fertilization (IVF) technology. In addition to San Francisco, CCRM has locations in Atlanta, Boston, Colorado, Houston, Minneapolis, New York, Orange County, Toronto, Canada, and a Northern Virginia location is slated to open summer 2017. Dr. Schoolcraft and his colleagues achieve some of the highest pregnancy rates in the country. CCRM has been ranked “The #1 Fertility Center in the U.S.” by Parents.com. To learn more, visit www.ccrmivf.com. Follow us on Facebook and Twitter.
Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia
SAN DIEGO, June 27, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct a Phase 1b/2 clinical trial of PCM-075, their polo-like kinase 1 (PLK1) inhibitor for the treatment of patients with acute myeloid leukemia (AML).
A Phase 1 safety study of PCM-075 was previously completed in patients with advanced or metastatic solid tumor cancers. In this phase 1 study, PCM-075 was administered orally, once daily for five consecutive days, every three weeks, to evaluate drug dosages, drug metabolism, first cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose (MTD). The current phase 1b/2 clinical trial submission is the first study planned to evaluate PCM-075 in patients with hematologic cancers.
“This is an exciting time for Trovagene as we expand our business to precision medicine therapeutics. We are pleased to have our IND and protocol for our Phase 1b/2 clinical trial submitted and under review by the FDA,” said Bill Welch, Chief Executive Officer of Trovagene. “There is a critical need for improved therapeutic options to treat AML and we believe PCM-075 holds significant promise for patients suffering from this disease. We look forward to providing additional details on the development of PCM-075 as we move forward with our clinical development plans.”
PCM-075 is a highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in several different hematologic malignancies, as well as solid tumors such as breast, prostate, ovarian, lung, gastric and colon cancers. PCM-075 is orally bioavailable and has been explored in an initial Phase 1, open-label, dose-escalation safety study in patients with advanced metastatic solid tumor cancers. Trovagene plans to initiate clinical trials of PCM-075 in AML, since it has significant advantages over prior PLK1 inhibitors evaluated in this indication, including a higher selectivity, greater potency, oral bioavailability and shorter half-life.
About Trovagene, Inc.
Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. For more information, please visit https://www.trovagene.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Trovagene’s expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful, or that Trovagene’s strategy to design its liquid biopsy tests to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2016, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
VP, Corporate Communications
SOURCE Trovagene, Inc.
CALGARY and SAN DIEGO, June 27, 2017 /PRNewswire/ – Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company) today announced that it has opened an office in San Diego, California. The office will support investor relations, business development and clinical operations functions.
“Expanding our operations into this leading biotech hub within one of the largest biopharmaceutical markets in the world, allows us to aggressively pursue our business development efforts and leverage the talent and expertise this region offers,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “Not only does it bring us closer to a pool of talent that will help us with preparation and execution of our planned phase three registration study in metastatic breast cancer, it also provides immediate proximity to our manufacturing group located in Carlsbad, California, which is responsible for our late-stage clinical lead agent REOLYSIN.”
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, an immuno-oncology viral agent, as a potential treatment for a variety of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Oncolytics’ clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study in breast cancer, as well as studies in combination with checkpoint inhibitors and IMID/targeted therapies in solid and hematological malignancies. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company’s belief as to the potential of REOLYSIN® as a cancer therapeutic; the Company’s expectations as to the success of its research and development programs in 2017 and beyond, the Company’s planned operations, the value of the additional patents and intellectual property; the Company’s expectations related to the applications of the patented technology; the Company’s expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company’s business and technologies involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
Evidence-based Health IT Company to Lead in Gut-Microbiome Science, Personalized Nutrition and the Ability to Accurately Predict Postprandial Glycemic Response
TEL AVIV, Israel and SAN FRANCISCO, June 27, 2017 /PRNewswire/ — DayTwo, a leader in microbiome-health management, announced today it has completed a $12.0 million Series A round of financing through Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Seventure Partners’ Health for Life Capital fund, Mayo Clinic, co-founder Marius Nacht, and other private investors.
The investment brings DayTwo’s total funding to $17.0 million, and will help the company to broaden and deepen its lead in evidence-based, clinically proven and actionable science of the gut microbiome. Proceeds from the financing will be used to expand the company’s product, engineering, and data science teams in Tel Aviv, Israel and San Francisco, California. In addition, DayTwo will deepen its clinical research with the Mayo Clinic and other gut-microbiome clinical research partners.
The Series A financing builds on an exceptional year for DayTwo, which saw a rapid growth in customers, key executive appointments, and market momentum in the areas of gut-microbiome-science, personalized nutrition, and diabetes and prediabetes management.
DayTwo is the first company to develop a method to accurately predict an individual’s glycemic response to specific foods and food combinations using an individual’s microbiome and other clinical factors. This evidence-based approach to nutrition is what enables DayTwo to bring personalized nutrition to market, and make personalized nutrition a reality for millions of people today.
“This ability to go beyond the informational offerings in the market, which are neither evidence-based, clinically proven, or actionable, makes DayTwo different and special. DayTwo will help people act upon a healthier, personalized diet, based on accurately predicting postprandial glycemic response,” said Nicholas Chia, professor of Biophysics & Microbiome at the Mayo Clinic in Rochester, Minnesota.
The DayTwo approach to health and nutrition recognizes that every individual has a unique gut microbiome and may respond very differently to the same food or food combinations. Day Two is currently the only offering in the market that can bring a personalized diet and nutrition plan to individuals, based on accurately predicting their own glycemic response. As postprandial glycemic response (post-meal blood sugar) is an independent risk factor for multiple diseases and affects weight gain and fat storage, maintaining normal blood glucose levels requires a nutrition plan that is tailored to the individual. DayTwo’s science is the only offering of its kind in the marketplace today.
DayTwo’s personalized nutrition offering is based on the original research led by Professors Eran Segal and Eran Elinav from the Weizmann Institute of Science in Israel, and published in the scientific journal Cell. Segal and Elinav found that by profiling an individual’s gut microbiome and leveraging machine learning, they can accurately predict an individual’s post-meal blood sugar response for unique foods and food combinations. This scientific and machine learning breakthrough has made personalized nutrition a reality today, and enables DayTwo to fulfill its mission to improve the health and wellbeing of millions, including diabetics and prediabetics, worldwide.
For consumers, DayTwo offers a cloud-based, first-of-its-kind, proprietary diet and nutrition planner, that enables individuals to get personalized scores for specific foods and food combinations based on their own gut-microbiome profile and other personal parameters.
For clinicians and health practitioners, DayTwo brings actionable insights for diet and nutrition to the care plans and meal plans of their patients; brings ease and convenience to adherence to a healthy diet; and provides an additional path for clinicians and their patients to stay connected. For nutrition, microbiome, weight-management, and meal planning businesses, DayTwo offers an API to access the DayTwo platform-as-a-service to provide predictive glycemic response scores for specific foods and food combinations.
“We’ve just scratched the surface of how powerful the microbiome is to support personalized diet, nutrition, and chronic condition management, to enable our customers to have the ability to live a full, happy and healthy lifestyle,” says DayTwo Chief Executive Officer Lihi Segal. “DayTwo has brought actionable, evidence-based science down to a mobile app, to make personalized nutrition easy and convenient for the first time. This enables DayTwo to impact the lives of hundreds of millions of people who struggle with diet and nutrition-related health risks every day,” added Segal. “Having the financial support and domain expertise of JJDC, Seventure, co-founder Marius Nacht and our Israeli private equity investor group will enable us to execute our vision even more rapidly and broadly – with consumers, practitioners, health centers, and medical device partners.”
Isabelle de Cremoux, CEO and Managing partner of Seventure Partners, added “Our investment in DayTwo fits very well into the focus of Health for Life Capital, as DayTwo acts on precise knowledge of an individual’s microbiome. DayTwo is positioned at the interface between nutrition and health, with an easy-to-use app which provides precisely tailored advice for each individual’s dietary needs.”
DayTwo provides personalized nutrition and actionable insights that allow consumers to live healthier and maintain normal blood sugar levels. DayTwo does this through DNA sequencing of the gut microbiome – the vast collection of bacteria, which is as unique to each individual as their fingerprints. DayTwo leverages the scientific and evidence-based understanding of the microbiome so consumers may take practical and immediate steps to improve their own health and wellbeing. The DayTwo service is based on six years of clinical research conducted by Professors Eran Segal and Eran Elinav from the Weizmann Institute of Science in Israel. Prof. Segal’s and Prof. Elinav’s research has been funded solely by the Weizmann Institute of Science and upon its completion, the research technology was licensed exclusively to DayTwo. The clinical research results on which our product and service is based have been published in the Nature, The Cell, Cell Metabolism, and a Research Video that can be found at https://www.daytwo.com/microbiomeandnutrition/theresearch. To learn more about DayTwo, visit http://www.daytwo.com.
About Johnson & Johnson Innovation – JJDC, Inc.
Johnson & Johnson Innovation – JJDC, Inc. is the venture capital subsidiary of Johnson & Johnson that has been investing since 1973 in the medical device, diagnostic, pharmaceutical, and consumer health areas. JJDC’s goal is to create opportunities that meet the strategic needs of its operating affiliates while providing visibility to innovative emerging technology, businesses and business models. JJDC invests in companies across the continuum from early stage seed investments to advanced stages of series venture management. For more information, please visit www.jjdc.com.
About Seventure Partners
With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe, Israel and North America. In Life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis, as well as entrepreneurs and financial institutions. Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank. For more details: www.seventure.com / Twitter @SeventureP
By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy, to prolong their life. Immunotherapy could further…
[[Click headline to continue reading.]]